CIP
BMRN icon

Chartwell Investment Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Chartwell Investment Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,803
Closed -$1.16M – 414
2017
Q2 		$1.16M Buy
12,803
+325
+3% +$29.6K 0.04% 344
2017
Q1 		$1.09M Sell
12,478
-71,882
-85% -$6.39M 0.04% 340
2016
Q4 		$6.99M Sell
84,360
-535,265
-86% -$46M 0.24% 151
2016
Q3 		$57.3M Buy
+619,625
New +$58.3M 1.02% 20
2016
Q2 		– Sell
-146,547
Closed -$12.1M – 402
2016
Q1 		$12.1M Sell
146,547
-15,978
-10% -$1.3M 0.23% 120
2015
Q4 		$17M Sell
162,525
-127,745
-44% -$13.3M 0.35% 80
2015
Q3 		$30.6M Buy
290,270
+55,570
+24% +$7.42M 0.66% 38
2015
Q2 		$32.1M Sell
234,700
-148,775
-39% -$18.4M 0.63% 45
2015
Q1 		$47.8M Buy
383,475
+258,685
+207% +$27.4M 0.93% 21
2014
Q4 		$11.3M Sell
124,790
-126,380
-50% -$10.5M 0.24% 180
2014
Q3 		$18.1M Sell
251,170
-1,950
-0.8% -$128K 0.41% 74
2014
Q2 		$15.7M Buy
253,120
+32,500
+15% +$1.96M 0.33% 126
2014
Q1 		$15M Buy
220,620
+36,100
+20% +$2.66M 0.31% 137
2013
Q4 		$13M Buy
184,520
+2,795
+2% +$190K 0.27% 163
2013
Q3 		$13.1M Sell
181,725
-53,900
-23% -$3.58M 0.3% 150
2013
Q2 		$13.1M Buy
+235,625
New +$14.7M 0.33% 122

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Chartwell Investment Partners's BMRN Position: Q3 2017 in Review

Chartwell Investment Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 12,803 shares — an estimated $1.16M sold.

Chartwell Investment Partners first reported a position in BMRN in Q2 2013 and held it in 16 quarters. The position peaked at $57.3M in Q3 2016. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

  • Chartwell Investment Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Chartwell Investment Partners sold 12,803 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $1.16M.
  • Chartwell Investment Partners first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Chartwell Investment Partners's BioMarin Pharmaceuticals position peaked at $57.3M in Q3 2016.
  • 411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Chartwell Investment Partners's 13F filing for Q3 2017, filed 8 Nov 2017.